OmniAb, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022; filed March 30, 2023. This is an annual report, not a standalone fourth-quarter filing. FY2021 figures are the primary comparable period. OmniAb completed its separation from Ligand and business combination on November 1, 2022; pre-separation results are carve-out financials and may not represent standalone costs or performance.
Business context
OmniAb provides antibody-discovery technologies to pharmaceutical and biotechnology partners, earning technology-access and research-service fees, development and commercial milestones, and royalties. At year-end, it reported 69 active partners, 291 active programs, 23 partner programs in clinical development, and three approved partner products. The company had 95 employees, including 74 in research and development.
Financial performance and liquidity
| Metric (USD millions, except percentages) | FY2022 | FY2021 |
|---|---|---|
| Revenue | $59.1 | $34.7 |
| Operating loss | $(26.6) | $(35.6) |
| Net loss | $(22.3) | $(27.0) |
| Net loss per share, basic and diluted | $(0.26) | $(0.33) |
| Cash used in operating activities | $(3.6) | $(5.7) |
- Revenue rose 70%. Milestones were $33.9 million (up 233%), service revenue $18.8 million (down 6%), license fees $5.1 million (up 12%), and royalty revenue $1.4 million, versus none reported in FY2021. Growth was driven chiefly by a teclistamab commercial-sale milestone and royalties on zimberelimab and sugemalimab sales in China.
- Operating expenses increased 22% to $85.7 million: research and development rose 23% to $48.4 million, general and administrative rose 47% to $24.9 million, and intangible amortization was $13.1 million. The net loss narrowed by $4.7 million. Approximate net loss margin improved to 38% from 78%; operating loss margin improved to 45% from 102%.
- Year-end cash and cash equivalents were $33.4 million and short-term investments were $54.9 million, or $88.3 million combined. Current assets were $125.0 million versus current liabilities of $26.0 million. The balance sheet reported no debt; lease liabilities totaled $25.8 million.
- Cash used in investing activities was $73.3 million, primarily purchases of short-term investments ($54.8 million) and property and equipment ($17.2 million). Financing provided $110.7 million, largely from the business combination and transfers from Ligand. Operating cash use included a $12.7 million increase in accounts receivable and a $9.5 million decrease in deferred revenue.
- Three partners contributed 72% of FY2022 revenue, versus 63% in FY2021. One partner alone represented 47% of FY2022 revenue.
Outlook, risks, and unusual items
- Management said existing cash, cash equivalents, short-term investments, and expected operating cash flows should support operations for at least the next 12 months. No specific revenue, earnings, or cash-flow guidance was provided.
- OmniAb received $35.0 million in teclistamab milestone payments in January 2023. It recognized $25.0 million as FY2022 revenue; the balance is expected to be recognized in 2023 under the license agreement.
- Management expects continued losses and substantial investment in platform R&D, commercial expansion, systems, personnel, and public-company costs. Longer-term value depends on partner milestones and royalties, but drug-development outcomes and timing are uncertain and controlled by partners.
- Key risks include revenue and partner concentration; partner termination or program setbacks; competition and technology adoption; dependence on third-party animal facilities and suppliers; intellectual-property and licensing exposure; regulation of genetically altered animals; cybersecurity and privacy; and market, banking, and financing conditions. The filing also describes potential indemnification and tax liabilities related to the separation from Ligand.
- The business combination and separation changed the company’s capital structure and reporting basis. FY2022 includes standalone reporting only from November 1; earlier periods include Ligand allocations. The audit opinion was unmodified, but management did not assess internal control over financial reporting for 2022 under the reverse-acquisition transition relief, and the auditor provided no internal-control attestation.
- The company reported no legal proceedings expected to have a material adverse effect. It recorded no goodwill or finite-lived intangible-asset impairment in 2022.
Important facts for investors to verify
- Whether partner concentration declines and the reported active programs progress into clinical development, milestones, and commercial sales.
- The composition, collectability, and timing of accounts receivable and deferred revenue, plus recognition of the remaining teclistamab milestone amount.
- Cash use and operating costs as a standalone public company, including R&D investment, share-based compensation, lease obligations, and public-company expenses.
- Partner-level revenue concentration and the reliability and completeness of partner-reported program-status metrics.
- Potential dilution from warrants, equity awards, earnout shares, and registered resale securities; warrants have an $11.50 exercise price and may produce no proceeds if not exercised.
- Separation-related obligations to Ligand, including tax and indemnification provisions, and the development of internal-control reporting in subsequent filings.